Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

The company's portfolio includes GIP antibody conjugates, including GLP-1 and other combinations, designed to address specific obesity subpopulations ... Helicore's R&D activities are supported by ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...

obesity class 1: BMI 30 kg/m 2 to 34.9 kg/m 2 obesity class 2: BMI 35 kg/m 2 to 39.9 kg/m 2 obesity class 3: BMI 40 kg/m 2 or more. Use clinical judgement when interpreting the healthy weight category ...

The company’s portfolio includes GIP antibody conjugates, including GLP-1 and other combinations, designed to address specific obesity subpopulations ... by world-class protein engineering ...

In Tuesday's issue of The Lancet Diabetes & Endocrinology, dozens of international medical experts and people with lived experience are proposing a major change to how obesity is diagnosed because ...

Kidney stone prevention centers around nutrition and lifestyle improvements. Learn what to eat, drink, avoid, and other ways ...